Bosutinib (Compound)
Synonyms:Bosutinib, 380843-75-4, SKI-606, Bosutinib (SKI-606), SKI 606, BOSULIF, SKI606, 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile, Bosutinib (USAN), Bosutinib [USAN], 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile, SK-606, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile, BOSUTINIB ISOMER 1, CHEMBL288441, 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile, 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile, CHEBI:39112, 5018V4AEZ0, SKI-606), Bosutinib (as monohydrate), Bosutinib [USAN:INN], NCGC00241107-01, UNII-5018V4AEZ0, MFCD07367846, Bosutinib,SKI-606, BOSUTINIB [INN], Bosutinib (SKI606), BOSUTINIB [MI], BOSUTINIB [VANDF], PF-5208763, Bosutinib - SKI-606, BOSUTINIB [MART.], EC 700-455-1, BOSUTINIB [WHO-DD], MLS006011212, SCHEMBL158390, AMY266, BDBM4552, GTPL5710, Bosutinib, >=98% (HPLC), DTXSID10861568, EX-A391, BCPP000318, HMS2043A22, HMS3244A03, HMS3244A04, HMS3244B03, HMS3651C03, HMS3672K11, HMS3743E09, 2-PYRIDIN-2-YLETHYLACETATE, K00615a, BCP01782, HB1323, NSC765694, NSC799367, SK 606, AKOS015902521, AC-2413, BCP9000446, CCG-208129, CS-0118, DB06616, NSC-765694, NSC-799367, PB30881, NCGC00241107-03, NCGC00241107-05, 4-(2,4-dichloro-5-methoxy-anilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile, AS-11064, HY-10158, SMR002530350, FT-0656231, S1014, SKI606; SKI 606; SK-I606, SW220197-1, A25014, D03252, AB01565836_03, EN300-7565041, Q894611, SR-01000941572, J-519931, Q-200745, SR-01000941572-1, BRD-K99964838-001-01-0, BRD-K99964838-001-06-9, Z2216885221, 3-Quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-, 3-QUINOLINECARBONITRILE, 4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHYL-1-PIPERAZINYL)PROPOXY)-, 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile, SKI-606;4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
Id:5328940
Description:nan
Analyze
CFDE DD-Knowledge Graph
The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Bosutinib's neighborhood in the knowledge graph.
GDLPA Landing Pages Links
The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Bosutinib.
Playbook Workflow Builder
The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Bosutinib.
Results found
Linked to
| Label | Description |
|
|---|---|---|---|
 | A Substance | ||
 | DrugPage Collection: (DrugCentralID:04359; PubChem_CID:5328940, FILE=drugcentral_drug_04359.json) | ||
| Metadatata for bosutinib |
DrugPage Collection: (DrugCentralID:04359; PubChem_CID:5328940, FILE=drugcentral_drug_04359.json)
Metadatata for bosutinib
DISPLAY PER PAGE
10
@CFDE Workbench 2025
The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.
The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.
@CFDE Workbench 2025